

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 39/193, 39/295, C12N 7/01, 7/04, 15/40, 15/86</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 95/32733</b> <b>(43) International Publication Date:</b> 7 December 1995 (07.12.95)
<b>(21) International Application Number:</b> PCT/US95/06739 <b>(22) International Filing Date:</b> 26 May 1995 (26.05.95) <b>(30) Priority Data:</b> 250,445 27 May 1994 (27.05.94) US <b>(71) Applicant:</b> THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL [US/US]; 300 Bynum Hall, Campus Box 4100, Chapel Hill, NC 27599 (US). <b>(72) Inventors:</b> JOHNSTON, Robert, E.; 101 Marin Place, Chapel Hill, NC 27514 (US). DAVIS, Nancy, L.; 415 Sharron Road, Chapel Hill, NC 27514 (US). SMITH, Jonathan, F.; 6936 Eyley Valley Flint Road, Sabillasville, MD 21780 (US). GRIEDER, Franziska, B.; 4998-517 Battery Lane, Bethesda, MD 20814 (US). <b>(74) Agents:</b> SIBLEY, Kenneth, D. et al.; Bell, Seltzer, Park & Gibson, P.O. Drawer 34009, Charlotte, NC 28234 (US).		<b>(81) Designated States:</b> AU, CA, HU, JP, KR, MX, NZ, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> METHOD OF INDUCING AN IMMUNE RESPONSE WITH A LIVE VENEZUELAN EQUINE ENCEPHALITIS VIRUS EXPRESSING A HETEROLOGOUS IMMUNOGEN  <b>(57) Abstract</b>  A method of protecting a subject against a disease comprises administering a recombinant Venezuelan Equine Encephalitis (VEE) Virus to the subject in an effective immunogenic amount, with the VEE virus containing a heterologous RNA segment, and with the heterologous segment comprising a promoter operable in the subject operatively associated with a sequence encoding an immunogenic protein or peptide effective for protecting the subject from the disease. Preferred promoters are VEE 26S subgenomic promoters, and preferred immunogens are viral immunogens. Novel attenuating mutations useful in carrying out the invention are also disclosed.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

**METHOD OF INDUCING AN IMMUNE RESPONSE WITH A  
LIVE VENEZUELAN EQUINE ENCEPHALITIS VIRUS  
EXPRESSING A HETEROLOGOUS IMMUNOGEN**

Field of the Invention

The present invention relates to live attenuated vaccines in general, and particularly relates to attenuated vaccine produced from Venezuelan Equine  
5 Encephalitis (VEE) virus.

Background of the Invention

Live, attenuated viral vaccines are among the most successful means of controlling viral disease. However, for some virus pathogens, immunization with a  
10 live virus strain may be either impractical or unsafe. One alternative strategy is the insertion of genes encoding immunizing antigens of such agents into the vaccine strain of another virus. However, relatively few such systems are currently available.

15 Hahn et al., *Proc. Natl. Acad. Sci. USA* 89, 2679 (1992), describes Sindbis virus constructs which express a truncated form of the influenza hemagglutinin protein. The constructs are used to study antigen processing and presentation *in vitro* and in mice.

20 Although no infectious challenge dose is tested, it is also suggested that such constructs might be used to produce protective B- and T-cell mediated immunity. The final paragraph of the discussion section states:

-2-

"Although SIN is not likely to be approved for use as a human vaccine, a parallel approach to the one used here for SIN may be applicable for developing live-attenuated vaccine strains using viruses with similar replication strategies, such as attenuated strains of Venezuelan equine encephalitis virus.... (citing Davis et al.)" Insofar as applicant is aware, a problem with the Sindbis vector is that the heterologous insert is unstable therein and is "kicked out" of the vector, with the practical limit for stable inserts being about 1 kb.

Davis et al., U.S. Patent No. 5,185,440, describes cDNAs encoding the VEE virus and attenuated mutations which may be incorporated therein for use in making a vaccine. The use of a subgenomic expression system is neither suggested nor disclosed.

#### Summary of the Invention

A first aspect of the present invention is a method of protecting a subject against a disease. The method comprises administering a recombinant Venezuelan Equine Encephalitis (VEE) virus to the subject in an effective immunogenic amount, with the VEE virus containing at least one attenuating mutation (and typically two or even three different attenuating mutations), and with the VEE virus containing a heterologous DNA segment. The heterologous DNA segment comprises a promoter operable in the subject operatively associated with a DNA encoding an immunogenic protein or peptide effective for protecting the subject from the disease. The heterologous insert may, optionally, itself serve as an attenuating mutation.

In one preferred embodiment, the heterologous DNA segment of the VEE virus is derived from the genome of a pathogenic organism. According to this embodiment, the heterologous DNA segment comprising the promoter operatively associated with the DNA encoding the immunogenic protein or peptide is effective for

-3-

protecting the subject from the disease caused by the pathogenic organism.

A second aspect of the present invention is a DNA comprising a cDNA clone coding for an infectious Venezuelan Equine Encephalitis (VEE) virus RNA transcript and a heterologous promoter positioned upstream from the cDNA clone and operatively associated therewith, and further comprising at least one attenuating mutation selected from the group consisting of codons at E1 amino acid 272 which specify an attenuating mutation; codons at E1 amino acid 81 which specify an attenuating mutation; and codons at E1 amino acid 253 which specify an attenuating mutation.

A third aspect of the present invention is a DNA comprising a cDNA clone coding for an infectious Venezuelan Equine Encephalitis (VEE) virus RNA transcript and a heterologous promoter positioned upstream from said cDNA clone and operatively associated therewith, and further comprising: (a) a first attenuating mutation which is a codon at E1 amino acid 253 which specifies an attenuating mutation; and (b) a second attenuating mutation which is an inactivated E3 amino acid 56 to 59 cleavage recognition site.

Further aspects of the present invention include an infectious VEE virus RNA transcript encoded by cDNA clones as given herein; infectious VEE virus particles containing such RNA transcripts; and pharmaceutical formulations comprising such infectious VEE virus particles, in an effective immunogenic amount, in a pharmaceutically acceptable carrier.

Frolov et al., *Proceedings IXth International Congress of Virology, Glasgow, Scotland, August 8-13, 1993*, pg. 67, discusses recombinant VEE viruses which express a Hepatitis B virus antigenic protein. The use of an attenuated VEE virus, strain 230, is described. However, it is not suggested that the attenuated virus itself be administered to humans. To the contrary, these

-4-

viruses are used to manufacture the antigenic Hepatitis B virus proteins themselves in tissue culture, which are then harvested and administered to humans. Strain 230 itself replicates poorly, if at all, in humans.

- 5           The foregoing and other objects and aspects of the present invention are explained in detail in the specification set forth below.

#### Brief Description of the Drawings

- 10           **Figure 1** is an illustration of the structure of the shuttle vector containing the structural genes of VEE with three attenuating mutations in the E2 gene, and a second 26S promoter and multiple cloning site inserted directly downstream from the C-terminus of E1, in the 3.2 kb pUC118 plasmid.

- 15           **Figures 2a-2c** illustrate double promoter vectors.

- 20           **Figure 3** is a Northern blot analysis of total intracellular RNA from baby hamster kidney (BHK) cells infected with an attenuated VEE mutant, with the mutant containing an HA gene inserted downstream of a second subgenomic promoter, or with the mutant containing an inserted HA gene in a non-coding orientation.

- 25           **Figures 4a-4d** illustrate the immunocytochemical staining of VEE vector-infected BHK cell monolayers. Cells were infected with either influenza PR/8/34, VEE vector containing the complete influenza HA gene, VEE vector without insert.

- 30           **Figures 5a-5c** are graphical illustrations of the clinical signs observed in inoculated mice challenged intranasally with influenza. Mice were inoculated with PBS, VEE vector without insert, or VEE vector with the complete influenza HA gene.

- 35           **Figure 6** is a graphical illustration of pre-viral challenge anti-flu IgG ELISA titers of serum obtained from inoculated mice. Mice were inoculated with

-5-

PBS, VEE vector without insert, or VEE vector with the complete influenza HA gene.

Figure 7 is a graphical illustration of the titer of viable influenza virus observed in lung tissue of inoculated mice 4 days after challenge with influenza. Mice were inoculated with PBS, VEE vector without insert, or VEE vector with the complete influenza HA gene.

#### Detailed Description of the Invention

Complementary DNA sequences encoding live Venezuelan Equine Encephalitis (VEE) virus and pharmaceutical formulations containing the same are known. See, e.g., N. Davis et al., U.S. Patent No. 5,185,440 (Applicant specifically intends that the disclosures of all patent references cited herein be incorporated herein by reference in their entirety).

The phrases "attenuating mutation" and "attenuating amino acid" as used herein mean a nucleotide mutation or an amino acid coded for in view of such mutation which result in a decreased probability of causing disease in its host (i.e., a loss of virulence), in accordance with standard terminology in the art (See, e.g., B. Davis et al., *Microbiology*, 132 (3d ed. 1980), whether the mutation be a substitution mutation or an in-frame deletion mutation. The phrase "attenuating mutation" excludes mutations which would be lethal to the virus. Examples of known VEE attenuating mutations include codons at E2 amino acid position 76 which specify an attenuating mutation, codons at E2 amino acid position 209 which specify an attenuating mutation, and codons at E2 amino acid 120 which specify an attenuating mutation (see, e.g., U.S. Patent No. 5,185,440 to N. Davis et al.); a G to C mutation at viral RNA nucleotide 3.

Novel attenuating mutations disclosed herein which may be used to carry out the present invention include codons at E1 amino acid 272 which specify an attenuating mutation (preferably a substitution mutation,

-6-

such as a threonine or serine (most preferably threonine)); codons at E1 amino acid 81 which specify an attenuating mutation (preferably a substitution mutation, such as an isoleucine or leucine (most preferably isoleucine)); and codons at E1 amino acid 253 which specify an attenuating mutation (preferably a substitution mutation such as a serine or threonine (most preferably serine)).

A novel pair of attenuating mutations which may be inserted together in a cDNA clone encoding an attenuated VEE virus is (a) a first attenuating mutation which is a codon at E1 amino acid 253 which specifies an attenuating mutation; and (b) a second mutation which is an inactivated E3 amino acid 56 to 59 cleavage recognition site. An advantage of this combination of attenuating mutations is that the inactivated cleavage site, of itself, is lethal to the virus. Thus, if the attenuating mutation at E1 amino acid 253 reverts to the virulent wild-type, the remaining mutation kills the virus. The E3 amino acid 56 to 59 cleavage recognition site may be inactivated by any suitable means: the cleavage recognition site may be deleted, in whole or in part; a substitution mutation may be made therein (e.g., an arginine to aspartic acid substitution mutation at amino acid 59).

Attenuating mutations may be introduced into cDNAs encoding live VEE by any suitable means, such as site-directed mutagenesis (see, e.g., U.S. Patent No. 4,873,192 to Kunkel).

The immunogenic protein or peptide, or "immunogen" may be any immunogen suitable for protecting the subject against a disease, including but not limited to microbial, bacterial, protozoal, parasitic, and viral diseases. For example, the immunogen may be an influenza virus immunogen (e.g., an influenza virus hemagglutinin (HA) surface protein, or an equine influenza virus immunogen), or a lentivirus immunogen (e.g., an equine



-7-

infectious anemia virus immunogen, a Human Immunodeficiency Virus (HIV) immunogen, such as an HIV-1 immunogen, or an HIV-2 immunogen). The immunogen may also be a coronavirus immunogen (e.g., a transmissible gastroenteritis virus immunogen for pigs, or an infectious bronchitis virus immunogen for chickens,) or a flavivirus immunogen (e.g., a yellow fever virus immunogen or a Japanese encephalitis virus immunogen). If desired, an advantage of the instant invention is that the heterologous insert containing the DNA encoding the immunogen as given above may be a relatively large insert, at least 1 kilobase in length.

The heterologous promoter is preferably a Venezuelan equine encephalitis virus 26S subgenomic promoter. This definition is intended to include derivatives of this promoter such as deletion mutants thereof, so long as activity as a promoter is retained.

Subjects which may be administered the live attenuated viruses and vaccine formulations disclosed herein include both human and animal (e.g., horse, donkey, pigs, mouse, hamster, monkey, chicken) subjects.

Vaccine formulations of the present invention comprise an immunogenic amount of a live attenuated virus as disclosed herein in combination with a pharmaceutically acceptable carrier. An "immunogenic amount" is an amount of the attenuated virus sufficient to evoke an immune response, particularly an immune response to the protein or peptide encoded by the heterologous DNA carried by the virus, in the subject to which the virus is administered. An amount of from about  $10^1$  to  $10^5$  plaque forming units of the live virus per dose is suitable, depending upon the age and species of the subject being treated. Exemplary pharmaceutically acceptable carriers include, but are not limited to, sterile pyrogen-free water and sterile pyrogen-free physiological saline solution.

-8-

Administration of the live attenuated viruses disclosed herein may be carried out by any suitable means, including both parenteral injection (such as intraperitoneal, subcutaneous, or intramuscular injection), by in ovo injection in birds, and by topical application of the virus (typically carried in the pharmaceutical formulation) to an airway surface. Topical application of the virus to an airway surface can be carried out by intranasal administration (e.g., by use of a dropper, swab, or inhaler which deposits a pharmaceutical formulation intranasally). Topical application of the virus to an airway surface can also be carried out by inhalation administration, such as by creating respirable particles of a pharmaceutical formulation (including both solid particles and liquid particles) containing the virus as an aerosol suspension, and then causing the subject to inhale the respirable particles. Methods and apparatus for administering respirable particles of pharmaceutical formulations are well known, and any conventional technique can be employed. See, e.g., U.S. Patent No. 5,304,125 to D. Leith; U.S. Patent No. 5,299,566 to C. Davis and R. Snyder; U.S. Patent No. 5,290,550 to R. Fisher and W. Metzger; and U.S. Patent No. 5,292,498 to R. Boucher.

The following examples are provided to illustrate the present invention, and should not be construed as limiting thereof.

#### EXAMPLE 1

##### Construction of a "Second Promoter" Expression Vector

A full-length cDNA clone derived from the TRD strain of VEE, pV3507, and containing three attenuating mutations in the E2 gene was employed in this study. The mutations occur at E2 76 lys, E2 120 lys and E2 209 lys, as reported in Davis et al., *Virology* 183:20 (1991). The cDNA clone was digested with Tth111I, converted to blunt ends with Klenow fragment of E. coli DNA polymerase, and

-9-

then digested with EcoRI. The 3.9 kb fragment was isolated and ligated with M12 mp19 RF DNA that had been digested with HindIII, treated with Klenow fragment and then digested with EcoRI. The resulting M13 phage, TE3, 5 contained the structural gene region of pV3507, but not the 26S promoter region. The HindIII site was regenerated in the ligation. Single-stranded DNA from phage was produced following transformation of E. coli CJ236 (*dut-ung-*) with TE3 and used in the procedure 10 outlined by Kunkel, *Proc. Natl. Acad. Sci. USA* 82:488 (1985), with a synthetic oligonucleotide designed to give the following insertion (in bold):

3' end of E1 gene - -34/+14 26S promoter-ClaI site - the 5' end of 3' untranslated region  
nt11,315-nt11,326 nt11,327-nt11,338

15 AAACATAATTGA/GAGGGGCCCTATAACTCTCTACGGCTAACCTGAATGGACTACGACATCG/ATACAGCAGCAA

(SEQ ID NO: 1) The regions flanking the inserted sequence are identified by nucleotide numbers based on the full-length VEE sequence, as identified by Kinney et al., *Virology* 170:19 (1989).

20 The correct insertion was identified initially by screening with ClaI digestion of phage RF DNA, and confirmed by sequencing across the junction between the E1 gene and the 3'-untranslated region on single-stranded phage DNA.

25 Thereafter, the DNA fragment containing the pV3507 structural genes and the inserted second 26S promoter was subcloned into pUC118 using HindIII and EcoRI. The HindIII and EcoRI sites were removed by digestion followed by conversion to blunt ends with 30 Klenow fragment and religation to form the pUC118 second promoter clone.

A 1.5 kb SalI-SalI "stuffer" fragment lacking an initiator AUG codon was isolated from the glycoprotein gene region of the TR5000 full-length Sindbis clone 35 (identified by Schoepp et al., *Virology* 193:149 (1993)), and inserted into the SalI site of the Cla12 adaptor

-11-

sequence was ligated to BamHI digested, dephosphorylated shuttle vector DNA. V4002 DNA was cut with ClaI and dephosphorylated. Thereafter, the ClaI fragment containing the HA sequence was purified from the shuttle  
5 vector and ligated to prepare V4002 DNA. Clones containing the HA gene in the multiple cloning site downstream of the second 26S promoter were identified using digestion with HpaI. Clones including both coding (pV4002HA) and noncoding (pV4002AH) orientations were  
10 identified. Tests for the specific infectivity of the transcripts from these clones showed that they were as infectious as parental transcripts, but that these HA-containing genomes made smaller plaques on baby hamster kidney (BHK) cell monolayers. From these results, we  
15 determined that the VEE expression vector containing the three attenuating mutations in E2 and an inserted 1.7 kb HA gene was still replication competent, but appeared to grow more slowly than the vector without an insert.

## EXAMPLE 3

20           Stability Test of HA Containing Vectors During  
                  Replication in Tissue Culture

Total RNA from vector-infected cells was analyzed for HA sequence-containing subgenomic RNA transcripts using Northern blots probed with VEE-specific  
25 or HA-specific probes as described in Sambrook et al., *Molecular Cloning* pp 7.39-7.52. Purified cytoplasmic RNA was glyoxylated, electrophoresed on agarose gels containing 0.01 M sodium phosphate (pH 7), and transferred to Biotrans nylon membranes (ICN) with 7.5 M  
30 sodium hydroxide. A VEE-specific <sup>32</sup>P-labeled riboprobe was made using a subclone of the VEE glycoprotein gene region (nt 9493 to 10486) in the pGEM3 transcription vector, pGEM19. The pGEM4 HA clone obtained from Dr. Andy Caton at the Wistar Institute was used to generate  
35 an HA-specific <sup>32</sup>P-labeled riboprobe. (The HA clone used contained a single nucleotide deletion which resulted in

-10-

plasmid. The Cla12 plasmid containing a multiple cloning site (mcs) flanked by ClaI sites was identified by Hughes et al., *J. Virol.* 61:3004 (1987).

Using ClaI, the multiple cloning site  
5 containing the inserted TR5000 sequence was cloned into the unique ClaI site of the pUC118 second promoter clone. Digestion with SalI and self-ligation produced the shuttle vector with the structure shown in Figure 1.

Thereafter, a viable full-length VEE second  
10 promoter expression vector including three attenuating mutations was prepared. The 3.4 kb AflIII-NotI fragment isolated from the shuttle vector and containing a portion of the viral structural genes, the inserted downstream second promoter and the 3'-untranslated region, was used  
15 to replace the homologous AflIII-NotI region of the pV3507 full-length clone. Transformants were screened with ClaI. Plasmids containing a ClaI site were linearized at the unique NotI site and transcribed *in vitro* with T7 RNA polymerase. Transcripts were quantitated by  
20 incorporation of alpha-<sup>32</sup>P-labeled UTP. Thereafter, monolayers were transfected with transcripts using cationic liposomes (Lipofectin, BRL) and then overlaid with agarose for assay of plaque formation. The transcripts had specific infectivities comparable to  
25 those produced from the virulent pV3000 parent clone, indicating that they were fully infectious. Figures 2a-2c illustrate double promoter vectors. Figure 2b is an illustration of pV4002, one of the downstream second promoter expression vectors.

30

## EXAMPLE 2

### Construction of an Expression Vector Containing the Influenza HA gene

The complete coding sequence of the HA gene  
from influenza strain PR/8 cloned into the BamHI site of  
35 pGem4 was obtained from Dr. Andy Caton at the Wistar  
Institute. The 1.7 kb BamHI fragment containing the HA

-12-

translation of a truncated protein. This mutation affected our ability to detect any expression of protein from this vector, although subgenomic HA-containing viral RNAs were detected.) Duplicate membranes were hybridized to either probe, dried and exposed to x-ray film. The results are illustrated in Figure 3. Lanes A and D contain total cytoplasmic RNA from cells infected with a VEE strain containing three attenuating mutations in E2. Lanes B and E contain total cytoplasmic RNA from cells infected with the same mutant strain with a second subgenomic promoter followed by the influenza HA gene in the coding orientation (V4002HA). Lanes C and F contain total cytoplasmic RNA from cells infected with the VEE vector containing the HA gene in the noncoding orientation (V4002AH). Lanes A, B and C were probed with a <sup>32</sup>P-labeled riboprobe complementary to a portion of the influenza HA gene. Lanes D, E and F were probed with a <sup>32</sup>P-labeled riboprobe complementary to a portion of the VEE glycoprotein genes. The positions of ribosomal RNA markers were determined in a parallel lane stained with ethidium bromide. VEE genome length RNA (40S) was not detectable in this experiment.

The results indicate that deletion mutants of both the V4002HA and V4002AH vectors were arising during replication in tissue culture. However, some subgenomic RNAs in V4002HA-infected cells still contained HA sequences, and a significant fraction of these were of a size to accommodate the complete HA gene. The results revealed some instability of the inserted sequence.

-13-

## EXAMPLE 4

Expression in Cultured BHK cells of Influenza PR/8 HA  
Gene from a Downstream Promoter Expression Vector  
with Two Attenuating Mutations

5           The complete coding sequence of the HA gene  
from influenza PR/8 cloned into the HindIII site of  
pBR322 was obtained from Dr. P. Palese at the Mt. Sinai  
School of Medicine. The HA-containing HindIII fragment  
was ligated to the HindIII-cut and dephosphorylated  
10 shuttle vector (see Figure 1). ClaI was then used to  
insert these HA sequences in both coding (V4036a) and  
noncoding (V4036e) orientations into a VEE second  
promoter expression vector that carried two attenuating  
mutations, E2 lys 209 and E1 thr 272. RNA transcribed in  
15 vitro from these clones showed comparable specific  
infectivities to RNA from the parental clone without the  
HA gene. Virus-containing supernatants obtained  
following transfection of BHK cells with cationic  
liposomes contained both small and large plaques, with  
20 the proportion of large plaques increasing with time. A  
greater proportion of large plaque variants were seen  
with V4036a, carrying HA in the coding orientation, than  
with V4036e.

BHK cell monolayers were infected at a  
25 multiplicity of 1 with either egg-grown influenza virus  
(PR/8 strain), the second promoter expression vector with  
the HA gene in the coding orientation, or the vector  
without the insert. At 6 hr post-infection, the  
monolayers were fixed with methanol:acetone (1:1) at  
30 20 °C and air dried. Using the horseradish peroxidase,  
biotin-avidin detection system (Vector labs), cells were  
tested for the presence of viral antigens using an HA-  
specific monoclonal antibody, or VEE-specific hyperimmune  
mouse ascites fluid, as primary antibodies. Cells were  
35 then counterstained with Meyer's hematoxylin. The  
monolayers infected with influenza PR/8 or with the  
coding HA vector showed positive staining for HA. The

-14-

results are illustrated in **Figures 4a-4d**. **Figure 4a** illustrates cells infected with influenza PR/8 stained with anti-HA antibody. **Figure 4b** illustrates VEE HA-vector infected cells stained with anti-HA antibody. **Figure 4c** illustrates cells infected with VEE vector without insert stained with anti-VEE antibody. **Figure 4d** illustrates cells infected with VEE vector without insert stained with anti-HA antibody.

The HA stain in HA vector infected cells was cytoplasmic, and was as intense, under these conditions, as the staining for HA in the influenza-infected control monolayers. These results indicate that influenza HA can be expressed at normal levels from the second 26S promoter in a form that is detectable by this anti-HA monoclonal antibody, and that an infectious VEE virus carrying the inserted gene can be produced.

## EXAMPLE 5

### Protection of Mice Against Influenza Challenge

Four-week-old CD-1 mice were inoculated subcutaneously into each rear footpad with  $1 \times 10^4$  pfu of (1) diluent (PBS) alone, (2) the HA-expressing doubly attenuated vector (V4036a), or with (3) the vaccine vector without insert. Three weeks later, the mice were challenged intranasally with  $10^5$  EID<sub>50</sub> (50% egg infectious dose) of influenza virus. The results are reported in **Figures 5a-5c**. All 24 control mice suffered severe disease and 50% died. Only one of 12 HA-vector-inoculated mice died, and another exhibited signs of disease for one day and recovered.

Pre-challenge anti-flu serum IgG ELISA titers were measured, and the results are illustrated in **Figure 6**. The geometric mean ELISA titer of anti-HA serum IgG in the HA-vector inoculated mice was 246, while sera from only 3 of 24 control mice gave a detectable titer, and they were positive only at the lowest dilution tested (1:50). The two HA-vector-inoculated mice affected by



-15-

the influenza challenge showed no detectable anti-HA IgG. Therefore, in 10 of 12 mice, the HA-vector elicited a detectable level of anti-HA serum IgG, and 11 of 12 mice were protected against lethal influenza challenge.

5

## EXAMPLE 6

Protection of Mice Against Influenza Challenge

Four-week-old CD-1 mice were inoculated subcutaneously into each rear footpad with  $1 \times 10^4$  pfu of (1) diluent (PBS) alone, (2) the HA-expressing doubly  
10 attenuated vector, or with (3) the vaccine vector without insert. Three weeks later, the mice were challenged intranasally with  $10^5$  EID<sub>50</sub> (50% egg infectious dose) of influenza virus. The lungs were removed 4 days after challenge. Lung tissue was homogenized in PBS + 0.1% BSA  
15 to give a 20% suspension, centrifuged, aliquoted and frozen at  $-70^\circ\text{C}$ . For each animal, two aliquots were assayed for pfu on MDCK cells under agarose containing 0.1% trypsin. No influenza infectivity was detected in the lungs of mice previously immunized with the HA-vector  
20 at a detection level of  $1.25 \times 10^2$  pfu/gm tissue (25 pfu/average lung). The geometric mean titers (represented by solid dots) calculated for the animals in the control groups with measurable virus titers, were  $3.04 \times 10^6$  pfu/gm for PBS-inoculated mice, and  $1.93 \times 10^6$   
25 pfu/gm for mice inoculated with VEE vector alone. The results are reported in Figure 7. The results suggest a very low level of challenge virus replication in the vaccinated animals.

The foregoing is illustrative of the present  
30 invention and is not to be construed as limiting thereof. The invention is defined by the following claims, with equivalents of the claims to be included therein.

-16-

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

(i) APPLICANT: Johnston, Robert E.  
Davis, Nancy L.  
Smith, Jonathon F.  
Grieder, Franziska B.

(ii) TITLE OF INVENTION: METHOD OF INDUCING AN IMMUNE RESPONSE  
WITH A LIVE VENEZUELAN EQUINE ENCEPHALITIS VIRUS  
EXPRESSING A HETEROLOGOUS IMMUNOGEN

(iii) NUMBER OF SEQUENCES: 1

## (iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Kenneth D. Sibley  
(B) STREET: Post Office Drawer 34009  
(C) CITY: Charlotte  
(D) STATE: North Carolina  
(E) COUNTRY: USA  
(F) ZIP: 28234

## (v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk  
(B) COMPUTER: IBM PC compatible  
(C) OPERATING SYSTEM: PC-DOS/MS-DOS  
(D) SOFTWARE: PatentIn Release #1.0. Version #1.25

## (vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: US 08/250,445  
(B) FILING DATE: 27-MAY-1994  
(C) CLASSIFICATION:

## (viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Sibley, Kenneth D.  
(B) REGISTRATION NUMBER: 31,665  
(C) REFERENCE/DOCKET NUMBER: 5470-79

## (ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (919) 420-2200  
(B) TELEFAX: (919) 881-3175

## (2) INFORMATION FOR SEQ ID NO:1:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 74 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

-17-

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

AAACATAATT GAGAGGGGCC CCTATAACTC TCTACGGCTA ACCTGAATGG ACTACGACAT 60

CGATACAGCA GCAA 74

-18-

## CLAIMS:

1. A method of protecting a subject against a disease, comprising:  
administering a recombinant Venezuelan Equine  
5 Encephalitis (VEE) virus to said subject in an effective immunogenic amount, with said VEE virus containing at least one attenuating mutation, and with said VEE virus containing a heterologous DNA segment, said heterologous  
10 DNA segment comprising a promoter operable in said subject operatively associated with a DNA encoding an immunogenic protein or peptide effective for protecting said subject from said disease.
2. A method according to claim 1, wherein said disease is a viral disease.
- 15 3. A method according to claim 1, wherein said immunogenic protein or peptide is selected from the group consisting of influenza immunogens, lentivirus immunogens, coronavirus immunogens, and flavivirus immunogens.
- 20 4. A method according to claim 1, wherein said heterologous DNA is at least 1 kilobase in length.
5. A method according to claim 1, wherein said heterologous DNA encodes an influenza immunogen.
- 25 6. A method according to claim 1, wherein said heterologous DNA encodes an influenza virus hemagglutinin (HA) surface protein.
7. A method according to claim 1, wherein said heterologous DNA encodes a lentivirus immunog n.

-19-

8. A method according to claim 1, wherein said heterologous DNA encodes a coronavirus immunogen.

9. A method according to claim 1, wherein said heterologous DNA encodes a flavivirus immunogen.

5 10. A method according to claim 1, wherein said subject is a horse and said heterologous DNA encodes an equine infectious anemia virus immunogen.

11. A method according to claim 1, wherein said heterologous promoter is a Venezuelan equine  
10 encephalitis virus 26S subgenomic promoter.

12. A method according to claim 1, wherein at least one attenuating mutation is selected from the group consisting of codons at E2 amino acid position 76 which specify an attenuating mutation, codons at E2 amino acid  
15 position 209 which specify an attenuating mutation, codons at E2 amino acid 120 which specify an attenuating mutation; a G to C mutation at viral RNA nucleotide 3; codons at E1 amino acid 272 which specify an attenuating mutation; codons at E1 amino acid 81 which specify an  
20 attenuating mutation; and codons at E1 amino acid 253 which specify an attenuating mutation.

13. A method according to claim 1, wherein said administering step is a parenteral administration step.

25 14. A method according to claim 1, wherein said administering step is carried out by topically applying said virus to an airway surface of said subject.

15. A method according to claim 1, wherein said administering step is an intranasal administration  
30 step.

-20-

16. A method according to claim 1, wherein said administering step is an inhalation administration step.

17. A DNA comprising a cDNA clone coding for  
5 an infectious Venezuelan Equine Encephalitis (VEE) virus  
RNA transcript and a heterologous promoter positioned  
upstream from said cDNA clone and operatively associated  
therewith, and further comprising at least one  
10 attenuating mutation selected from the group consisting  
of codons at E1 amino acid 272 which specify an  
attenuating mutation; codons at E1 amino acid 81 which  
specify an attenuating mutation; and codons at E1 amino  
acid 253 which specify an attenuating mutation.

18. An infectious VEE virus RNA transcript  
15 encoded by a cDNA clone of claim 17.

19. Infectious VEE virus particles containing  
an RNA transcript of claim 18.

20. A pharmaceutical formulation comprising  
infectious VEE virus particles according to claim 19 in  
20 an effective immunogenic amount in a pharmaceutically  
acceptable carrier.

21. A DNA comprising a cDNA clone coding for  
an infectious Venezuelan Equine Encephalitis (VEE) virus  
RNA transcript and a heterologous promoter positioned  
25 upstream from said cDNA clone and operatively associated  
therewith, and further comprising:

a first attenuating mutation which is a codon  
at E1 amino acid 253 which specifies an attenuating  
mutation; and

30 a second mutation which is an inactivated E3  
amino acid 56 to 59 cleavage recognition site.

-21-

22. A DNA according to claim 21, wherein said E3 amino acid 56 to 59 cleavage recognition site is deleted.

23. A DNA according to claim 21, wherein said  
5 E3 amino acid 56 to 59 cleavage recognition site contains an inactivated substitution mutation.

24. A DNA according to claim 21, wherein said  
inactivating E3 amino acid 56 to 59 cleavage recognition  
site contains an arginine to aspartic acid substitution  
10 mutation at amino acid 59.

25. An infectious VEE virus RNA transcript encoded by a cDNA clone of claim 21.

26. Infectious VEE virus particles containing an RNA transcript of claim 25.

15 27. A pharmaceutical formulation comprising infectious VEE virus particles according to claim 26 in an effective immunogenic amount in a pharmaceutically acceptable carrier.

1/6




FIG. 1.




FIG. 2a.




FIG. 2b.




FIG. 2c.



2/6





FIG. 3

3/6




**FIG. 4a**



**FIG. 4b**



**FIG. 4c**



**FIG. 4d**

4/6




FIG. 5a.




FIG. 5b.

5/6




FIG. 5c.




FIG. 6.



# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US95/06739

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 39/193; 39/295; C12N 7/01, 7/04, 15/40, 15/86

US CL : 424/199.1, 218.1; 536/24.72; 435/235.1

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/199.1, 218.1; 536/24.72; 435/235.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US, A, 5,185,440 (DAVIS ET AL) 09 FEBRUARY 1993, see entire document.	1-16
Y	Proceedings of the National Academy of Sciences USA, Volume 89, issued January 1992, London et al, "Infectious enveloped RNA virus antigenic chimeras", pages 207-211, see entire document.	1-16
Y	Journal of Virology, Volume 67, Number 11, issued November 1993, Bredenbeek et al, "Sindbis Virus Expression Vectors: Packaging of RNA Replicons by Using Defective Helper RNAs", pages 6439-6446, see entire document.	4

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	Y	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	Z	document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

08 SEPTEMBER 1995

Date of mailing of the international search report

22 SEP 1995

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Authorized officer

MARY E. MOSHER

Facsimile No. (703) 305-3230

Telephone No. (703) 308-0196

**INTERNATIONAL SEARCH REPORT**International application No.  
PCT/US95/06739**C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Archives of Virology Supplementum, Number 9, issued March 1994, Davis et al, "A molecular genetic approach to the study of Venezuelan equine encephalitis virus pathogenesis", pages 99-109, see entire document.	17-27

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US95/06739

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark n Protest

☐

The additional search fees were accompanied by the applicant's protest.

☐

No protest accompanied the payment of additional search fees.



## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US95/06739

### B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

U.S. Automated Patent System, Medline, Biosis, CAB. Keywords: Davis NL, sindbis, recombinant, equine, enceph?, VEE, attenuat?, E1, E3, process?, cleav?, semliki, toga?, alphavir?, alpha, virus, viral, ross river, sequenc?, vaccine.

### BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claim (s)1-16, drawn to immunization method using attenuated VEE containing a heterologous insert.  
Group II, claim(s) 17-27, drawn to VEE with specified attenuating mutations, nucleic acids encoding the same, and pharmaceutical compositions.

The inventions listed as Groups I-II do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: Group I is drawn to a first process of using VEE virus, and group II is drawn to VEE viruses and materials used in making the viruses. The group I process requires VEE virus having a heterologous insert, while the group II products do not require a heterologous insert. Therefore the group I process involves a special technical feature lacking in the group II products. Furthermore, the group I process as broadly claimed does not require the particulars of the attenuating mutations as required in group II. Accordingly, the claims are not so linked by a special technical feature within the meaning of PCT Rule 13.2 so as to form a single inventive concept.